Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Sees Benefit From Medicare Rx In Short Term, But Risk For Zyprexa

Executive Summary

Lilly expects a "modest benefit" from implementation of Medicare Part D that could later be offset by increased pricing pressures

You may also be interested in...



Old Tricks In New Designs: Part D Increasing Commercial Plan Design Options

Medicare Part D is giving drug plans an opportunity to use more restrictive pharmacy benefit designs that had previously not been palatable to the commercial sector

Old Tricks In New Designs: Part D Increasing Commercial Plan Design Options

Medicare Part D is giving drug plans an opportunity to use more restrictive pharmacy benefit designs that had previously not been palatable to the commercial sector

For Lilly Sales Force The Future Is Now: Reorg Emphasizes Sales Specialists

Lilly is focused on increasing sales team efficiency - not reducing overall headcount - with its "sales force of the future" reorganization

Related Content

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel